-
Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into a partnership with Biocre Tech, a specialist in protein and peptide research headquartered in Shenzhen. The collaboration aims to leverage the expertise of both companies, although financial details of the agreement were not disclosed. This…
-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership with Beijing Highthink Pharmaceutical Technology Service Co., Ltd. The collaboration is aimed at providing Contract Research Organization (CRO) services, specifically to support a clinical study for Apeloa’s generic version of semaglutide. Under the terms of…
-
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech. The collaboration aims to establish an antibody drug conjugate (ADC) platform that offers a range of diversified antibodies, highly active small molecule payloads, and linker technology. The…
-
Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of a Phase III clinical study for its salfaprodil injection, which is being developed as a treatment for acute ischemic stroke. Salfaprodil is a novel NMDA receptor antagonist. According to the public data, Apeloa first filed…
-
Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced a significant ten-year partnership agreement with Wuhan Hesheng Technology Co., Ltd. While the financial specifics of the deal remain undisclosed, the collaboration is poised to enhance both companies’ capabilities in the pharmaceutical sector. Collaboration Focused…
-
Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced an investment of USD 2 million to establish a wholly owned subsidiary, Apeloa Europe GmbH, in Germany. This strategic move is aimed at deepening the company’s globalization strategy, expanding its global market presence, and enhancing…
